web analytics
25 C
Munich
Thursday, August 11, 2022

Plandai Biotechnology Inc (OTCMKTS: PLPL) Reverse Merger Biotech Gearing Up For Enormous Week Ahead

Plandai Biotechnology Inc (OTCMKTS: PLPL) continues to move northbound in recent trading moving up another 44% on Friday alone. Good things are happening for the Company; On Wednesday the Company announced the SEC has canceled civil penalties and interest totaling approximately $200,000 related to the Commission’s 2018 action against the Company and its former Chairman of the Board and CEO, Mr. Roger Duffield. This comes after a 2-year quiet period during which time the Company cleared out $7 million in debt leaving them debt free. Plandai continues its due diligence and discussions pertaining to the possible licensing deal with Puri Blood, as well as other acquisition opportunities. In addition, the company is in the process of engaging a PCAOB audit firm to complete a two-year audit of the company as part of an effort to file registration statement with the SEC. Simply becoming an SEC filer would triple the market cap of Plandai or more. 

Recently the Company signed an LOI with Puriblood Medical Co., Ltd whereby, Jessie Chiang Chiang via entities she controls, will license to Plandai the exclusive rights to the Puriblood technology for North, Central, and South America for a period of 30 years and will acquire the controlling interest in the Company and will become the Company’s Director, President, and Chief Executive Officer. This is a biotech reverse merger. Reverse merger stocks can be more explosive than biotech’s when the incoming Company has real value but is undiscovered to investors and we have covered many on the website that have gone from pennies to dollars. Two recent RM runners that stand out are TSNP which went from sub pennies (where we first wrote about it) to several dollars per share. The other is HRBR which went from a few cents (where we first wrote about it) to $3 plus. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Plandai Biotechnology Inc (OTCMKTS: PLPL) is a publicly quoted shell company domiciled in Nevada seeking to create value for its shareholders by merging with another entity with experienced management and opportunities for growth. PLPL still owns intellectual properties related to its prior research, development and production of botanical extracts including trademarks, trade secrets, and product formulations for green tea and citrus products from discontinued operations. The Company’s intellectual properties were the result of research and development endeavors with North-West University in Potchefstroom, South Africa, and the Company’s former Senteeko Tea Estate located in Mpumalanga, South Africa. PLPL historically had a massive debt problem, 2 years ago there was over $20 million in liabilities on the books, many of them convertible that has all be cleared out now leaving Plandai virtually debt free. 

Microcapdaily has been reporting on Plandai for many years; back in 2016 we reported on the Company: “PLPL products include Phytofare™ Catechin Complex, a water-soluble powder, Ph2™ Topical Catechin Complex, a topical cream that has Phytofare™ nano-entrapped in Pheroid™, Ph2™ Oral Catechin Complex, a gel tab version of Phytofare™ nano-entrapped in Pheroid™, suitable for oral consumption, and Ph2™ Liquid Catechin Complex, an oral version of Phytofare™ nano-entrapped in Pheroid™ in a liquid suspension, suitable for mixing into beverages and liquid medications.” 

To Find out the inside Scoop on PLPL Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

PLPL

Puriblood Medical Co., Ltd. [Taipei Exchange], develops and sells blood cell separation products including its leukocyte reduction filters for red blood cells, platelets, and whole blood, as well as real-time filtration sets for whole blood. The Puriblood Leukocyte Reduction Blood Filtration System helps ensure the quality of blood used for transfusions, by effectively removing Leukocytes from blood, thereby minimizing acute or delayed adverse transfusion reactions, including infection and death. Currently, approximately thirty countries around the world require leuko-reduction in blood supplies. Puriblood’s core blood purification filters reduce up to over 99% of leukocytes, in substantially less time, with minimal blood loss, while retaining a high level of red blood cells (where a higher number of red blood cells retained is desirable). Puriblood’s technology is patented in multiple strategic countries, including the United States, and cleared for marketing by the U.S. Food and Drug Administration under Section 510(k) of the Federal Food, Drug, and Cosmetic Act. Puriblood is a U.S. registered trademark of Puriblood Medical Co., Ltd. Corporation Taiwan 2f., No. 11, Gongye E. 9th Rd. Hsinchu County 30075 Taiwan R.O.C. 

Under the terms of the proposed agreement, the current holder of the worldwide rights, exclusive of Taiwan, Jessie Chiang, via entities she controls, will license to Plandai the exclusive rights to the Puriblood technology for North, Central, and South America for a period of 30 years. Upon closing of the proposed transaction, Ms. Chiang will acquire the controlling interest in the Company and will become the Company’s Director, President, and Chief Executive Officer. Ms. Chiang will then appoint new members to the board of directors and will move to establish a board of advisors consisting of leading industry, finance, and business experts. 

Tad Mailander, the Company’s CEO and director commented, “We have been very clear with our shareholders that Plandai has planned to create increased value by merging with another business entity or implementing a positive change in business direction via a new management team. We have been carefully vetting such opportunities, and we are now pleased to present this opportunity to our shareholders. We view this proposed transaction as being in the best interest of our shareholders. Our team is looking forward to completing our due diligence process and ultimately closing on this transaction.” 

The global leukapheresis market is primarily driven by solid growth in voluntary blood donations, rising incidence of hematologic diseases, such as leukemia, and an aging population in many countries. As a result, several industry analysts are forecasting continued strong growth in technologies and products designed for this market. For example, Quince Market Insights, in a report issued late in 2021, estimates the global leukapheresis market will grow at a compound annual growth rate of 43.9% until 2030. 

While the parties have agreed to non-binding terms in a letter outlining their intentions, the transaction has not yet been consummated, and there is no assurance that any such transaction will ultimately close. Plandai plans to release additional information concerning the progress of the proposed transaction as soon as possible, upon the completion of its due diligence investigation. 

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $9 million market valuation Plandai has 7,006,411,205 shares outstanding and 5,176,257,801 shares currently in the float. They sound like big numbers but PLPL is trading at $0.0013. Management has been hard at work behind the scenes over the past 2 years whipping out millions in debt leaving Plandai a perfect RM candidate with a low float and virtually now debt. As we have been saying reverse merger stocks can be more explosive than biotech’s when the incoming Company has real value but is undiscovered to investors and we have covered many on the website that have gone from pennies to dollars. PLPL RM has significant potential from current levels. In addition, the company is in the process of engaging a PCAOB audit firm to complete a two-year audit of the company as part of an effort to file registration statement with the SEC. Simply becoming an SEC filer would triple the market cap of Plandai or more. Puriblood’s technology is patented in multiple strategic countries, including the United States, and cleared for marketing by the U.S. Food and Drug Administration under Section 510(k) of the Federal Food, Drug, and Cosmetic Act. We initially gave the heads up on Plandai on June 15 when the stock was $0.0007. Microcapdaily will be covering Plandai / Puriblood RM as it happens so make sure you subscribe to Microcapdaily right now so you don’t miss it. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in PLPL either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.